(4/4) "These findings suggest that ALPS-derived metrics may not provide a direct measure of glymphatic function but rather reflect underlying axonal geometry. Interpretations of ALPS-derived metrics as biomarkers of glymphatic function must consider these anatomical complexities"
July 27, 2025 at 1:06 PM
(4/4) "These findings suggest that ALPS-derived metrics may not provide a direct measure of glymphatic function but rather reflect underlying axonal geometry. Interpretations of ALPS-derived metrics as biomarkers of glymphatic function must consider these anatomical complexities"
(3/4) and this study by Georgiopoulos & team (academic.oup.com/braincomms/a...) showing biases due to crossing fibers. We extend this to undulations/dispersion.
(3/4) and this study by Georgiopoulos & team (academic.oup.com/braincomms/a...) showing biases due to crossing fibers. We extend this to undulations/dispersion.
(2/4) motivated by this beautiful study by Adam Wright (onlinelibrary.wiley.com/doi/10.1002/...) where they show that radial asymmetry (what DTI-ALPS measures) exists throughout all WM, regardless of vascular orientation. We confirm this and show it exists at high b-values.
(2/4) motivated by this beautiful study by Adam Wright (onlinelibrary.wiley.com/doi/10.1002/...) where they show that radial asymmetry (what DTI-ALPS measures) exists throughout all WM, regardless of vascular orientation. We confirm this and show it exists at high b-values.
(2/3) we show these can be used to (A) define normative trajectories across pathways (B) identify developmental milestones (C) detect deviation from normal (examples in AD, MCI, epilepsy, Autism, ADHD, Depression, Anxiety) (D) provide centile scores for new out of sample datasets
May 11, 2025 at 8:49 PM
(2/3) we show these can be used to (A) define normative trajectories across pathways (B) identify developmental milestones (C) detect deviation from normal (examples in AD, MCI, epilepsy, Autism, ADHD, Depression, Anxiety) (D) provide centile scores for new out of sample datasets
Considerations and recommendations from the ISMRM Diffusion Study Group for preclinical diffusion MRI: Part 3—Ex vivo imaging: Data processing, comparisons with microscopy, and tractography
Considerations and recommendations from the ISMRM Diffusion Study Group for preclinical diffusion MRI: Part 3—Ex vivo imaging: Data processing, comparisons with microscopy, and tractography
Considerations and recommendations from the ISMRM diffusion study group for preclinical diffusion MRI: Part 2—Ex vivo imaging: Added value and acquisition
Considerations and recommendations from the ISMRM diffusion study group for preclinical diffusion MRI: Part 2—Ex vivo imaging: Added value and acquisition